Financials
Financial year 2025
Strybol Sint-Gillis from Brugge, company number BE0896926732, closed financial year 2025 with a result of € 21,125 after tax. For that financial year Strybol Sint-Gillis recorded a gross margin of € 17,391 and equity of € 142,338. Compared with financial year 2024, the result moved from € -1,296 to € 21,125. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 2, 2026.
€ 142,338
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 21,125
▲ still € 1,297 loss in 2024
Profit after tax over the fiscal year.
€ 18,506
▲ € 17,262 vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 21,000 paid out
99 % of the profit went to the shareholders, the rest stayed in the company.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 536
Supplier invoices still open on the last day of the fiscal year.
€ 46
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 34,601 | € -944 | € -3,329 | € 17,391 | ▲ € 20,720 |
| Profit after taxes | € 37,722 | € 388 | € -1,296 | € 21,125 | ▲ € 22,421 |
| Equity | € 143,122 | € 143,510 | € 142,213 | € 142,338 | |
| Total debts | € 37,956 | € 291 | € 0 | € 21,581 | |
| Cash | € 7,275 | € 5,432 | € 1,244 | € 18,506 | ▲ € 17,262 |
| Retained profit | € 124,522 | € 124,910 | € 123,613 | € 123,738 | |
| Dividend | € 37,500 | € 0 | € 0 | € 21,000 | |
| Balance sheet total | € 181,078 | € 143,801 | € 142,213 | € 163,919 | ▲ 15% |
Key figures of Strybol Sint-Gillis, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Strybol Sint-Gillis?
What happened at Strybol Sint-Gillis in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 21,125. Source: NBB ↗
- Strybol Wout Pharma BV became a director. NBB
- Strybol Iben Pharma BV became a director. NBB
- Strybol Invest BV became a director. NBB
- New establishment in Brugge. KBO
- Start of the company according to the CBE. KBO
In short
From € 37,722 profit in 2022 to € 21,125 profit in 2025.
Paid € 247 in corporate taxes since 2022.
Best year ever: 2022, with € 37,722 profit.
Paid out € 58,500 in dividends to the owners in total.
A new publication or filing at Strybol Sint-Gillis? We notify you, reason included.
Follow Strybol Sint-GillisDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Strybol Wout Pharma, Strybol Iben Pharma, Strybol Invest comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
Strybol Sint-GillisBehind Strybol Sint-Gillis are Strybol Wout Pharma BV, Strybol Iben Pharma BV and Strybol Invest BV. The shares are held by Strybol Wout Pharma (45%), Strybol Iben Pharma (45%) and Strybol Invest (10%).
Directors
According to the 2025 annual accounts
Director · represented by Strybol Wout
Also active at: STRYBOL DE ZEVEN TORENTJES, APOTHEEK SMEKENS, Strybol Invest, PHARMA 310505, Strybol Pharma Groep, Strybol De Berken
since 2024
Director · represented by Strybol Iben
Also active at: STRYBOL DE ZEVEN TORENTJES, APOTHEEK SMEKENS, Strybol Invest, PHARMA 310505, Strybol Pharma Groep, Strybol De Berken
since 2024
Director · represented by Strybol Geert
Also active at: De Rotonde Apotheek, APOTHEEK DEBAENST, APOTHEEK SMEKENS, DE VELTEM INVEST, De Berken Apotheek
since 2024
Shareholders
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Annuntiatenstraat 56
8000 Brugge
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0896.926.732
- VAT number
- BE 0896.926.732
- Registered office
- Annuntiatenstraat 56, 8000 Brugge
- Names & denominations
- Strybol Sint-Gillis
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 3 April 2008
- Peppol
- Active · Active since 30 Jan 2025
- Activities · NACE
Lease van intellectuele eigendom en vergelijkbare producten, met uitzondering van werken onder auteursrecht
Overige zakelijke dienstverlening, neg